Cargando…

Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”

Malignant pleural effusion represents a prognostic negative factor on survival conferring stage IV disease. The median of survival is 5 months and a 5-year survival of about 3%. We describe the therapeutic success obtained from different strategies in anaplastic lymphoma kinase (ALK) inhibitors in 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caterino, Umberto, Cesaro, Cristiano, Zamparelli, Enzo, Cesaro, Flavio, Palma, Alba, Lucci, Raffaella, Imitazione, Pasquale, Casazza, Dino, Amore, Dario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647055/ https://www.ncbi.nlm.nih.gov/pubmed/34950005 http://dx.doi.org/10.1159/000520127

Ejemplares similares

Unusual Periaortic Mediastinal Recurrence of Pulmonary Adenocarcinoma: When Making Diagnosis Is Really Necessary
por: Caterino, Umberto, et al.
Publicado: (2022)

Transbronchial needle aspiration in severe cardiac failure patient: ‘The old bull knows best’
por: Caterino, Umberto, et al.
Publicado: (2023)

Acquired Benign Tracheoesophageal Fistula: An Alternative Tracheoplastic Technique
por: Amore, Dario, et al.
Publicado: (2022)

Accessory right V(6) behind the bronchus intermedius during VATS right upper lobectomy
por: Amore, Dario, et al.
Publicado: (2019)

Uncommon anomalies of the left pulmonary artery during VATS lobectomy for lung cancer
por: Amore, Dario, et al.
Publicado: (2020)

Multiple variations in pulmonary veins during a thoracoscopic right lower lobectomy: A case report
por: Amore, Dario, et al.
Publicado: (2020)

Mediastinal malignant mesothelioma discovered in a patient with dysphagia
por: Amore, Dario, et al.
Publicado: (2020)

Left pulmonary artery pseudoaneurysm secondary to post‐operative lung abscess
por: Amore, Dario, et al.
Publicado: (2020)

Accessory V(6) during thoracoscopic middle lobectomy: “an uncomfortable presence”
por: Amore, Dario, et al.
Publicado: (2020)

Drainage of middle lobe vein into anomalous right lower lobe vein: management during thoracoscopic lobectomy
por: Amore, Dario, et al.
Publicado: (2020)

Conversion to thoracotomy during VATS segmentectomy for treatment of symptomatic endobronchial hamartoma
por: Amore, Dario, et al.
Publicado: (2018)

Elective surgery treatment in patient living in rural area with history of recurrent primary spontaneous pneumothorax: A procedure to avoid in absence of pneumothorax. A case report
por: Caterino, Umberto, et al.
Publicado: (2018)

Left lower lobectomy and partial preservation of segmental arteries of left upper lobe: A strategy to avoid pneumonectomy in selected cases
por: Amore, Dario, et al.
Publicado: (2019)

Noninvasive measurement of transdermal drug delivery by impedance spectroscopy
por: Arpaia, Pasquale, et al.
Publicado: (2017)

Incidental synchronous bronchial tumour: an unusual bronchoscopic finding
por: Caterino, Umberto, et al.
Publicado: (2020)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Endometrial cancer with an EML4-ALK rearrangement
por: Craig, Jeffrey W., et al.
Publicado: (2018)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

A micro-bioimpedance meter for monitoring insulin bioavailability in personalized diabetes therapy
por: Arpaia, Pasquale, et al.
Publicado: (2020)

Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements
por: Cha, Yoon Jin, et al.
Publicado: (2014)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Penetrating pulmonary injury caused by a steel rod
por: Amore, Dario, et al.
Publicado: (2020)

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
por: Amatu, Alessio, et al.
Publicado: (2015)

Overview of ALK and ROS1 Rearranged Lung Cancer
por: Choi, Chang Min
Publicado: (2013)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Peng, Ling, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

One lung ventilation management in a patient with Reinke’s edema
por: Rispoli, Marco, et al.
Publicado: (2020)

Atypical Carcinoid Tumor with Anaplastic Lymphoma Kinase (ALK) Rearrangement Successfully Treated by an ALK Inhibitor
por: Nakajima, Masayuki, et al.
Publicado: (2016)

Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor()
por: Chen, Xinru, et al.
Publicado: (2017)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
por: Iwama, Eiji, et al.
Publicado: (2014)

Frequency of ALK Rearrangement by FISH Testing and its Correlation with ALK-IHC in Adenocarcinoma of Primary Lung Origin
por: Moatter, Samar, et al.
Publicado: (2018)

PI3Kβ inhibition enhances ALK‐inhibitor sensitivity in ALK ‐rearranged lung cancer
por: Talwelkar, Sarang S., et al.
Publicado: (2023)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

Sweyjawbu expression is a predictor of ALK rearrangement status in lymphoma
por: Xue, Kai, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bca9u49naos8vl0ak3nhq3bebj